Cardio-Renal Registry

Sponsor
Queen Mary University of London
Study ID
NCT06521801
Status
Recruiting
Apply to this trial

Conditions

  • Cardio-Renal Syndrome
  • Cerebrovascular Accident
  • Dialysis
  • End Stage Renal Disease
  • Myocardial Infarction
  • Percutaneous Coronary Intervention

Eligibility Criteria

Sex
ALL
Age
16 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Observation — OTHER
    Observation

Study Details

Cardiovascular disease is the leading cause of morbidity and mortality among patients with chronic kidney disease (CKD). Even after adjustment for known cardiovascular risk factors, including diabetes and hypertension, mortality risk progressively increases with worsening CKD. As glomerular filtration rate (GFR) declines the probability of developing coronary artery disease (CAD) increases linearly, and patients with GFR \<60 mL/min/1.73 m2 have 2-3-fold increased CV mortality risk, relative to patients without CKD. Management of CAD is complicated in CKD patients due to the likelihood of comorbid conditions and potential for side effects. Despite their high cardiovascular risk, ACS patients with renal dysfunction are less commonly treated with guideline-based medical therapy and are less frequently referred for coronary revascularisation. This observation, referred to as the "treatment risk paradox," has been well described and may be explained by physicians' concerns regarding possible nonrenal side effects as well as renal toxicities. Furthermore, patients with severe CKD have traditionally been under-represented in most large cardiovascular clinical trials. Therefore, recommendations for both medical and revascularisation of CAD have relied heavily on extrapolation of results from the non-CKD population. This data will add to that literature by assessing the characteristics and outcomes of patients with CAD and CKD. It will also identify and characterise predictors of outcomes, improve risk stratification and diagnostic evaluation.

Key Dates

First listed
Jul 26, 2024
Start date
Aug 1, 2024
Status verified
Jan 2026
Primary completion
Jun 1, 2030
Completion
Jun 1, 2030

Study Design

Enrollment
60,000 participants (estimated)

Arms

  • Arm: Patients with Renal Disease or Cardiology Disease
    This study aims to assess, in a real-world setting, the safety, efficacy and feasibility of further investigations in patients with renal disease and cardiac disease.

Primary Outcome Measure

Mortality [ Time Frame: 30 days and 1 year ]

Central Contacts

Find similar trials

Nationwide
Stroke trialsNeurology trialsBrain disorders trials

Related Studies